Patient population
pneumonitis, active leptomeningeal disease, malignancy, cancer, autoimmune diseases, infections, Tumors, pulmonary disease
BRAIN METASTASIS, PNEUMONITIS, PULMONARY FIBROSIS, CANCER, AUTOIMMUNE DISEASES, LUNG DISEASES, INFECTIONS, TUMORS, INTERSTITIAL LUNG DISEASE, PULMONARY DISEASE, DISEASES
Eligible patients were 18 years of age or older with at least one measurable lesion as defined per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 [Key exclusion criteria included prior therapy with an anti-PD-1 or anti-PD-L1 therapy; active leptomeningeal disease or uncontrolled brain metastasis; active autoimmune diseases or history of autoimmune diseases that may relapse; any other active malignancy in the 2 years before the first dose of study treatment (except for any locally recurring cancer treated curatively); any condition that required systemic treatment with either corticosteroids or other immuno-suppressive medication ≤14 days before administration of study treatment; significant pulmonary disease or history of interstitial lung disease, non-infectious pneumonitis or uncontrolled diseases including pulmonary fibrosis and acute lung diseases; and severe chronic or active infections requiring systemic therapy. Full eligibility criteria are described in the 